Weight Gain and Metabolic Abnormalities During Extended Risperidone Treatment in Children and Adolescents
- 1 April 2009
- journal article
- research article
- Published by Mary Ann Liebert Inc in Journal of Child and Adolescent Psychopharmacology
- Vol. 19 (2) , 101-109
- https://doi.org/10.1089/cap.2008.007
Abstract
Objective: The aim of this study was to investigate the prevalence of clinical and laboratory metabolic abnormalities during long-term risperidone treatment in children and adolescents. Methods: Medically healthy 7- to 17-year-old children chronically treated, in a naturalistic setting, with risperidone were recruited through child psychiatry clinics. Anthropometric measurements and laboratory testing were conducted. Developmental and medication histories were obtained from medical records. Results: In 99 patients treated with risperidone for an average of 2.9 years, a significant increase in age- and gender-adjusted weight and body mass index (BMI) (i.e., z-scores) was observed. Concomitant treatment with psychostimulants did not attenuate this weight gain. Risperidone-associated weight gain was negatively correlated with the BMI z-score obtained at the onset of risperidone treatment. Compared to lean children, overweight and obese children had higher odds of metabolic abnormalities, including increased waist circumference, hypertriglyceridemia, and low high-density lipoprotein cholesterol (HDL-C). They also tended to have a higher insulin level and homeostasis model assessment insulin resistance (HOMA-IR) index. As a result, upon recruitment in the study, children with excessive weight were 12 times more likely to have at least one laboratory metabolic abnormality and seven times more likely to have at least one criterion of the metabolic syndrome compared to lean subjects. In contrast to excessive weight status, gaining ≥0.5 BMI z-score point during risperidone treatment was not associated with a significantly higher occurrence of metabolic disturbances. Conclusions: The long-term use of risperidone, especially when weight is above normal, is associated with a number of metabolic abnormalities but a low prevalence of the metabolic syndrome phenotype. Future studies should evaluate the stability of these abnormalities over time.Keywords
This publication has 45 references indexed in Scilit:
- Defining the Metabolic Syndrome in Children and Adolescents: Will the Real Definition Please Stand Up?The Journal of Pediatrics, 2008
- Body Mass Indexes and Lipid Profiles in Hospitalized Children and Adolescents Exposed to Atypical AntipsychoticsJournal of Child and Adolescent Psychopharmacology, 2007
- Antipsychotic drug-induced weight gain mediated by histamine H1receptor-linked activation of hypothalamic AMP-kinaseProceedings of the National Academy of Sciences, 2007
- Prevalence and Determinants of Insulin Resistance Among U.S. AdolescentsDiabetes Care, 2006
- Long-Term Use of Risperidone in Children with Disruptive Behavior Disorders and Subaverage Intelligence: Efficacy, Safety, and TolerabilityJournal of Child and Adolescent Psychopharmacology, 2006
- Overweight in Children and AdolescentsCirculation, 2005
- The Fourth Report on the Diagnosis, Evaluation, and Treatment of High Blood Pressure in Children and AdolescentsPediatrics, 2004
- Binding of antipsychotic drugs to human brain receptorsLife Sciences, 2000
- Variations in the Pattern of Pubertal Changes in BoysArchives of Disease in Childhood, 1970
- Variations in pattern of pubertal changes in girls.Archives of Disease in Childhood, 1969